4.7 Article

Detection and investigation of invasive mould disease

期刊

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
卷 66, 期 -, 页码 i15-i24

出版社

OXFORD UNIV PRESS
DOI: 10.1093/jac/dkq438

关键词

galactomannan; beta-d-glucan; PCR-based diagnosis; microscopic examination; cultures

资金

  1. Pfizer
  2. Pfizer International Operations
  3. Pfizer Inc.
  4. Astellas Pharma
  5. bioMerieux
  6. Gilead Sciences
  7. Schering Plough
  8. Soria Melguizo SA
  9. European Union
  10. ALBAN program
  11. Spanish Agency for International Cooperation
  12. Spanish Ministry of Culture and Education
  13. Spanish Health Research Fund
  14. Instituto de Salud Carlos III
  15. Ramon Areces Foundation
  16. Mutua Madrilena Foundation
  17. Austrian Science Fund (FWF) [P174840]
  18. MFF Tirol
  19. Merck Sharp
  20. Dohme
  21. Ministry of Health of the Czech Republic
  22. Schering-Plough/MSD

向作者/读者索取更多资源

A comprehensive review of diagnostic techniques for opportunistic systemic mycoses focused on invasive mould disease in immunocompromised patients is presented. We first analysed conventional diagnostic methods, such as microscopy examination, culture and radiology, underlining their limitations, which have led to the development of alternative methods, such as the detection of fungal components. Among these we highlight fungal antigen and DNA quantification, which make it possible to detect infections early and start appropriate treatment. We also briefly review the methods for carrying out susceptibility tests for antifungal drugs, including reference procedures, commercial techniques and their indications. Furthermore, we analyse the recommendations for therapeutic drug monitoring of antifungal agents in body fluids.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据